IONIC PHARMACEUTICALS, LLC
Brookline, MA · Biotech · Private
Expansile nanoparticles (eNPs) loaded with paclitaxel for intraperitoneal chemotherapy delivery to peritoneal tumors
- Grants
- $7.1M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Improving delivery of paclitaxel to ovarian cancer via expansile nanoparticles | $283,122 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Fluorescent nanoparticles to improve resections of microscopic pancreatic tumors | $296,990 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Fluorescent nanoparticles to improve resections of microscopic pancreatic tumors | $296,990 | |
| Federal grant | Department of Health and Human Services · Phase I · Production of a dissolvable hydrogel-based wound dressing for second degree burns | $225,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Treating Peritoneal Malignancies with Paclitaxel-Loaded Expansile Nanoparticles | $2,000,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Treating Peritoneal Malignancies with Paclitaxel-Loaded Expansile Nanoparticles | $982,798 | |
| Federal grant | Department of Health and Human Services · Phase II · Treating Peritoneal Malignancies with Paclitaxel-Loaded Expansile Nanoparticles | $1,017,202 | |
| Federal grant | Department of Health and Human Services · Phase II · Production of a dissolvable hydrogel-based wound dressing for second degree burns | $830,300 | |
| Federal grant | Department of Health and Human Services · Phase II · Production of a dissolvable hydrogel-based wound dressing for second degree burns | $866,742 | |
| Federal grant | Department of Health and Human Services · Phase I · Treating Second-Degree Burn Wound Infections with a Quorum Sensing Inhibitor | $300,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3163 | ANTEL BIOSYSTEMS, INC | — | — |
| 3164 | TORRALVA MEDICAL THERAPUETICS LLC | — | — |
| 3165 | Smart Biomolecules, Inc. | — | — |
| 3166 | IONIC PHARMACEUTICALS, LLC | — | — |
| 3167 | Sitryx Therapeutics | — | — |
| 3168 | SCHEDULE 1 THERAPEUTICS INC | — | — |
| 3169 | CURATIX, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Formulation Of Wound Dressings And The Uses Thereofapplication
- Formulation Of Wound Dressings And The Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.